Tango Therapeutics TNGX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -206.2%+150pp | -178.4%+168pp | -165.9%+156pp | -647.3%-336pp | -355.9%-17.1pp | |
| Net margin | -188.2%+135pp | -162.9%+147pp | -151.1%+133pp | -599.1%-325pp | -322.7%-22.8pp | |
| Returns | ||||||
| Return on equity | -38.4%+22.9pp | -37.2%+20.3pp | -51.7%-2.9pp | -76.1%-25.5pp | -61.3%-15.9pp | |
| Return on invested capital | -57.7%+18.7pp | -51.3%+23.4pp | -64%-3.9pp | -87.5%-23.6pp | -76.4%-20.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 27.4×+21.1× | 16.3×+9.3× | 8.9×+0.9× | 4.7×-2.7× | 6.3×-2.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.2×+0.1× | 0.3×+0.1× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $2.73+80.4% | $2.98+63.1% | $1.36-35.7% | $1.22-46.6% | $1.51-38.2% | |
| Valuation | ||||||
| Market capitalization | $2.99B+1,915% | $1.19B+259% | $934.59M+12.1% | $580.99M-37.4% | $148.11M-80.8% | |
| Price / sales | 52.4×+48.8× | 19.1×+11.2× | 14.1×-5.2× | 23.9×+2.1× | 3.6×-17.1× | |
| Price / book | 7.6×+6.7× | 3.4×+1.8× | 5.8×+2.2× | 4.3×+0.6× | 0.9×-2.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tango Therapeutics's ratios come from?
- Every ratio is computed from Tango Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
